â‚©
6450.00
Nov 27
Business Description
SeouLinBioscience Co Ltd
ISIN : KR7038070009
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | 0.9 | |||||
Interest Coverage | 5.96 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 3.88 | |||||
Beneish M-Score | -2.98 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.2 | |||||
3-Year EBITDA Growth Rate | -38.2 | |||||
3-Year EPS without NRI Growth Rate | -38.8 | |||||
3-Year Book Growth Rate | 10.2 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 42.54 | |||||
9-Day RSI | 36.6 | |||||
14-Day RSI | 35.39 | |||||
6-1 Month Momentum % | -17.54 | |||||
12-1 Month Momentum % | -19.34 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.98 | |||||
Quick Ratio | 4.98 | |||||
Days Inventory | 133.07 | |||||
Days Sales Outstanding | 40.72 | |||||
Days Payable | 53.09 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 1.55 | |||||
Dividend Payout Ratio | 0.64 | |||||
Forward Dividend Yield % | 1.55 | |||||
5-Year Yield-on-Cost % | 1.55 | |||||
3-Year Average Share Buyback Ratio | -1.2 | |||||
Shareholder Yield % | 28.79 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 21.89 | |||||
Operating Margin % | 5.61 | |||||
Net Margin % | -0.81 | |||||
FCF Margin % | 5.2 | |||||
ROE % | -0.79 | |||||
ROA % | -0.59 | |||||
ROIC % | 7.38 | |||||
ROC (Joel Greenblatt) % | 5.03 | |||||
ROCE % | 2.02 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio without NRI | 41.66 | |||||
PS Ratio | 0.67 | |||||
PB Ratio | 0.66 | |||||
Price-to-Tangible-Book | 0.65 | |||||
Price-to-Free-Cash-Flow | 12.47 | |||||
Price-to-Operating-Cash-Flow | 11.4 | |||||
EV-to-EBIT | 17.8 | |||||
EV-to-EBITDA | 11.49 | |||||
EV-to-Revenue | 0.38 | |||||
EV-to-FCF | 6.83 | |||||
Price-to-Projected-FCF | 0.6 | |||||
Price-to-Median-PS-Value | 0.41 | |||||
Price-to-Graham-Number | 1.09 | |||||
Price-to-Net-Current-Asset-Value | 1.25 | |||||
Earnings Yield (Greenblatt) % | 5.62 | |||||
FCF Yield % | 7.77 | |||||
Forward Rate of Return (Yacktman) % | 4.37 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
SeouLinBioscience Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil â‚©) | 82,093.027 | ||
EPS (TTM) (â‚©) | -77.669 | ||
Beta | 1.28 | ||
Volatility % | 21.6 | ||
14-Day RSI | 35.39 | ||
14-Day ATR (â‚©) | 204.493225 | ||
20-Day SMA (â‚©) | 6714 | ||
12-1 Month Momentum % | -19.34 | ||
52-Week Range (â‚©) | 6130 - 12240 | ||
Shares Outstanding (Mil) | 8.44 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
SeouLinBioscience Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
SeouLinBioscience Co Ltd Stock Events
Event | Date | Price(â‚©) | ||
---|---|---|---|---|
No Event Data |
SeouLinBioscience Co Ltd Frequently Asked Questions
What is SeouLinBioscience Co Ltd(XKRX:038070)'s stock price today?
When is next earnings date of SeouLinBioscience Co Ltd(XKRX:038070)?
Does SeouLinBioscience Co Ltd(XKRX:038070) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |